Black Rock Inc. Eq Rx, Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$1.66 - $2.31 $2.11 Million - $2.94 Million	1,273,052 Added 5.71%	23,553,172 $52.3 Million
Q2 2023 Aug 11, 2023	BUY	$1.61 - $1.96 $10 Million - $12.2 Million	6,238,616 Added 38.89%	22,280,120 $41.4 Million
Q1 2023 May 12, 2023	BUY	$1.8 - $2.83 $277,232 - $435,870	154,018 Added 0.97%	16,041,504 $31.1 Million
Q4 2022 Feb 13, 2023	BUY	$2.05 - $5.5 $4.87 Million - $13.1 Million	2,375,712 Added 17.58%	15,887,486 $39.1 Million
Q3 2022 Nov 14, 2022	BUY	$0.94 - $5.99 $3.1 Million - $19.7 Million	3,294,717 Added 32.25%	13,511,774 $66.9 Million
Q2 2022 Aug 12, 2022	BUY	$3.2 - $5.69 $22.6 Million - $40.2 Million	7,064,255 Added 224.06%	10,217,057 $47.9 Million
Q1 2022 May 12, 2022	BUY	$2.8 - $7.39 $8.83 Million - $23.3 Million	3,152,802 New	3,152,802 $13 Million

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.